title: Agonist-specific role for Na+-H+ antiport in prostaglandin release from microvessel endothelium.
abstract: Rabbit coronary microvascular endothelial (RCME) cells synthesize prostaglandin (PG) I2 and PGE2 in response to stimulation with human thrombin, ATP, and the Ca2+ ionophore, A23187. Replacement of extracellular Na+ with choline or N-methylglucamine reduced thrombin-stimulated PG secretion but did not significantly affect either ATP- or A23187-stimulated PG secretion. Pretreatment of RCME cells with Na+ channel or Na+ -Ca2+ exchange blockers did not alter PG release in response to any of these three agonists. Pretreatment of RCME cells with the specific Na+ -H+ antiport blockers 5-(N-ethyl-N-isopropyl)-amiloride (EIPA, 10 microM) and 5-(N,N-hexamethylene)-amiloride (HMA, 0.1 microM) significantly reduced thrombin but not A23187- or ATP-stimulated PG secretion. Studies with the intracellular pH indicator dye 2,7-bis(carboxyethyl)-5(6)-carboxyfluorescein demonstrated thrombin activation of Na+ -H+ antiport, an effect blocked by either HMA or EIPA. Since manipulations known to inhibit Na+ -H+ exchange (EIPA, HMA, replacement of Na+ with choline or N-methylglucamine) reduced thrombin-stimulated RCME cell PG release, we conclude that activation of Na+ -H+ exchange is involved in the coupling of thrombin interaction with RCME cells to subsequent phospholipase activation and PG release.
authors.affiliation: Department of Physiology, New York Medical College, Valhalla 10595.
authors.forename: M E
authors.initials: ME
authors.lastname: Gerritsen
authors.forename: C A
authors.initials: CA
authors.lastname: Perry
authors.forename: T
authors.initials: T
authors.lastname: Moatter
authors.forename: E J
authors.initials: EJ
authors.lastname: Cragoe
authors.forename: M S
authors.initials: MS
authors.lastname: Medow
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology; D000584:Amiloride / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport; D000001:Calcimycin / Q000494:pharmacology; D002352:Carrier Proteins / Q000378:metabolism; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D011464:Epoprostenol / Q000378:metabolism; D005452:Fluoresceins; D005456:Fluorescent Dyes; D006863:Hydrogen-Ion Concentration; D008833:Microcirculation / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism*; D011522:Protons; D011817:Rabbits; D012964:Sodium / Q000378:metabolism*; D017923:Sodium-Hydrogen Exchangers; D013917:Thrombin / Q000494:pharmacology
chemical_list: D002352:Carrier Proteins; D005452:Fluoresceins; D005456:Fluorescent Dyes; D011453:Prostaglandins; D011522:Protons; D017923:Sodium-Hydrogen Exchangers; C057360:5-(N,N-hexamethylene)amiloride; D000001:Calcimycin; D000584:Amiloride; C043829:2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein; D000255:Adenosine Triphosphate; D012964:Sodium; D011464:Epoprostenol; D013917:Thrombin; D015232:Dinoprostone; C039614:ethylisopropylamiloride